Press Releases

pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2009 WATERTOWN, Mass., Feb 11, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for

pSivida Corp Announces Second Quarter 2010 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Feb 04, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) (FF:PV3), a leading drug delivery company, today announced that its financial results for the second

pSivida CEO To Discuss Ocular Drug Delivery in Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 in London WATERTOWN, Mass., Jan 20, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of tiny, sustained-release drug delivery

More patients receiving either the High Dose or Low Dose Iluvien showed improvement in best corrected visual acuity of 15 or more letters at 2 years compared to those receiving sham treatment. This was statistically significant.pSivida's licensee, Alimera Sciences, plans to file New Drug Application (NDA) in the second quarter of 2010.

pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009 WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 12, 2009-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for

pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 5, 2009-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company, today announced that its financial results for the first

pSivida Announces Completion of BrachySil(TM) Dose Ranging Study in Pancreatic Cancer WATERTOWN, Mass., Oct 21, 2009 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company today announced the completion of a second pancreatic clinical trial of BrachySil

Top Line 24-Month Results Expected Mid-December from Pivotal Phase III Trial for Potential First Drug Treatment for Diabetic Macular Edema

pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien(R) Study WATERTOWN, Mass., Sep 29, 2009 (BUSINESS WIRE) -- pSivida Corp (NASDAQ: PSDV)(ASX: PVA), a leading drug delivery company that has developed two of the only three products approved by the FDA for

pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009 WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 24, 2009-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved

pSivida Anounces New Iluvien(R) Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 23, 2009-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company that has developed two of the only three products

pSivida CEO to Discuss New Technologies in Retinal Drug Delivery at 5th Annual Ophthalmic Drug Development and Delivery Summit BOSTON --(BUSINESS WIRE)--Sep. 18, 2009-- pSivida Corp , (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr.

pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 17, 2009-- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), (FF:PV3), a leading drug delivery company, today announced that its financial results for the

pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference BOSTON --(BUSINESS WIRE)--Sep. 9, 2009-- pSivida Corp , (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced it will webcast a live presentation at the Rodman & Renshaw Annual Health Care

Potential Additional Eye Disease Treatment Applications for the Company's Iluvien Product

pSivida Corp. Reports Results for the Quarter ended March 31, 2009 WATERTOWN, MA – May 14, 2009 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with the only two ophthalmic sustained delivery products approved by the FDA for treatment of back of the eye diseases, today

Highlights Emerging Technologies and Clinical Data on New and Existing Products

pSivida's Iluvien Phase III Study passes final DSMB Review Watertown, MA. (April 9, 2009) – pSivida Corp. (NASDAQ:PSDV, ASX:PVA, FF:PV3), a leading drug delivery company, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase III

pSivida CEO to Present at IBC Ocular Angiogenesis Conference Boston, MA (March 30, 2009) – pSivida Corp., (NASDAQ:PSDV, ASX:PSD, FF:PV3), a leading drug delivery company, today announced that Dr. Paul Ashton, President and Chief Executive Officer, will make a presentation on ocular drug delivery

Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study Watertown, MA - March 13, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic